{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:06:02Z","timestamp":1783487162245,"version":"3.55.0"},"reference-count":36,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>Double vision (diplopia) is a major determinant of work disability in patients with Graves' orbitopathy (GO), but is not part of the classification NOSPECS classification of GO.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>The objectives of the study were to quantitate diplopia in patients with moderate to severe GO and to study associations with other disease and patient variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design:<\/jats:title>\n                  <jats:p>This was a single-center prospective study of consecutive patients at the time of referral.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting:<\/jats:title>\n                  <jats:p>The study was conducted at the University Hospital Thyroid-Eye Clinic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients:<\/jats:title>\n                  <jats:p>Patients included 216 patients diagnosed with moderate to severe and active GO.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures:<\/jats:title>\n                  <jats:p>Binocular diplopia in field of gaze and monocular fields of motility were prospectively recorded on diagrams and measured by planimetry. Fields of diplopia were correlated to other disease and patient variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Six patients had only one functional eye and were excluded. Among the remaining 210 patients, diplopia was present in 75.2%. In patients with diplopia, this ranged from 5% to 100% (observed in 11.4% of patients) of binocular field of gaze. The field of diplopia correlated positively with eye motility restriction and with asymmetrical affection of orbits but negatively with signs of inflammation and proptosis that often are the main outcome measures in clinical studies of GO therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>Diplopia is very common in moderate to severe GO and a major cause for active therapy. In moderate to severe GO, the field of diplopia correlates negatively with some other indicators of disease activity, which may be explained by the physiological properties of binocular fusion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2014-4557","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T16:55:54Z","timestamp":1424364954000},"page":"2098-2105","source":"Crossref","is-referenced-by-count":15,"title":["Double Vision Is a Major Manifestation in Moderate to Severe Graves' Orbitopathy, but It Correlates Negatively With Inflammatory Signs and Proptosis"],"prefix":"10.1210","volume":"100","author":[{"given":"Peter","family":"Laurberg","sequence":"first","affiliation":[{"name":"Departments of Endocrinology (P.L., I.B.P., A.C.), Aalborg University, DK-9000 Aalborg Denmark;"},{"name":"Aalborg University Hospital, and Institute of Clinical Medicine (P.L., I.B.P., S.A.), Aalborg University, DK-9000 Aalborg Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia C.","family":"Berman","sequence":"additional","affiliation":[{"name":"Ophthalmology (D.C.B.), Aalborg University, DK-9000 Aalborg Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge B\u00fclow","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology (P.L., I.B.P., A.C.), Aalborg University, DK-9000 Aalborg Denmark;"},{"name":"Aalborg University Hospital, and Institute of Clinical Medicine (P.L., I.B.P., S.A.), Aalborg University, DK-9000 Aalborg Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Andersen","sequence":"additional","affiliation":[{"name":"Geriatric Medicine (S.A.), Aalborg University, DK-9000 Aalborg Denmark;"},{"name":"Aalborg University Hospital, and Institute of Clinical Medicine (P.L., I.B.P., S.A.), Aalborg University, DK-9000 Aalborg Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Carl\u00e9","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology (P.L., I.B.P., A.C.), Aalborg University, DK-9000 Aalborg Denmark;"},{"name":"Diagnostic Centre (A.C.), Silkeborg Hospital, DK-8600 Silkeborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071615140626800_B1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"2020071615140626800_B2","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1172\/JCI26031","article-title":"Thyrotropin receptor-associated diseases: from adenomata to Graves' disease","volume":"115","author":"Davies","year":"2005","journal-title":"J Clin Invest"},{"key":"2020071615140626800_B3","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615140626800_B4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/EJE-11-0548","article-title":"Incidence of hyperthyroidism in Sweden","volume":"165","author":"Abraham-Nordling","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"2020071615140626800_B5","doi-asserted-by":"crossref","first-page":"165487","DOI":"10.1155\/2014\/165487","article-title":"Association between TSH-receptor autoimmunity, hyperthyroidism, goitre, and orbitopathy in 208 patients included in the remission induction and sustenance in Graves' disease study","volume":"2014","author":"Laurberg","year":"2014","journal-title":"J Thyroid Res"},{"key":"2020071615140626800_B6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"European Group on Graves' Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2020071615140626800_B7","first-page":"444","article-title":"Prevalence and natural history of Graves' orbitopathy in the XXI century","volume":"36","author":"Piantanida","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"2020071615140626800_B8","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/jc.2012-1275","article-title":"Incidence and clinical presentation of moderate to severe Graves' orbitopathy in a Danish population before and after iodine fortification of salt","volume":"97","author":"Laurberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615140626800_B9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/thy.2010.0417","article-title":"Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists","volume":"21","author":"Bahn","year":"2011","journal-title":"Thyroid"},{"key":"2020071615140626800_B10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"European Group on Graves' Orbitopathy (EUGOGO)","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2020071615140626800_B11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF03345275","article-title":"Effects of Graves' ophthalmopathy on quality of life","volume":"27","author":"Wiersinga","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"2020071615140626800_B12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1210\/jc.2012-3119","article-title":"Public health relevance of Graves' orbitopathy","volume":"98","author":"Ponto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615140626800_B13","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1210\/jcem-29-7-982","article-title":"Classification of the eye changes of Graves' disease","volume":"29","author":"Werner","year":"1969","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615140626800_B14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00002341-199512000-00001","article-title":"Evolution of classification systems for Graves' ophthalmopathy","volume":"11","author":"Bartley","year":"1995","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2020071615140626800_B15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.iop.0000235499.34867.85","article-title":"VISA classification for Graves orbitopathy","volume":"22","author":"Dolman","year":"2006","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2020071615140626800_B16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/jcem-37-2-276","article-title":"Supervoltage orbital radiotherapy for Graves' ophthalmopathy","volume":"37","author":"Donaldson","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615140626800_B17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1210\/jcem-44-1-203","article-title":"Modification of the classification of the eye changes of Graves' disease: recommendations of the ad hoc committee of the American Thyroid Association","volume":"44","author":"Werner","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615140626800_B18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","article-title":"Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy","volume":"16","author":"Bahn","year":"1987","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020071615140626800_B19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"2020071615140626800_B20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/thy.1992.2.235","article-title":"Classification of eye changes of Graves' disease","volume":"2","author":"European Thyroid Association, Japanese Thyroid Association (Asia-Oceania Thyroid Association), Latin-American Thyroid Association, American Thyroid Association","year":"1992","journal-title":"Thyroid"},{"key":"2020071615140626800_B21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archopht.123.3.356","article-title":"A modified method for measuring uniocular fields of fixation: reliability in healthy subjects and in patients with Graves orbitopathy","volume":"123","author":"Haggerty","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"2020071615140626800_B22","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00417-010-1596-2","article-title":"Uniocular and binocular fields of rotation measures: octopus versus Goldmann","volume":"249","author":"Rowe","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2020071615140626800_B23","volume-title":"Stereological Methods. Practical Methods for Biological Morphometry","author":"Weibel","year":"1979"},{"key":"2020071615140626800_B24","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0161-6420(82)34647-3","article-title":"Functional scoring of the binocular field","volume":"89","author":"Esterman","year":"1982","journal-title":"Ophthalmology"},{"key":"2020071615140626800_B25","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/S0161-6420(87)33247-6","article-title":"Functional scoring of the field of binocular single vision in patients with diplopia","volume":"94","author":"Woodruff","year":"1987","journal-title":"Ophthalmology"},{"key":"2020071615140626800_B26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0161-6420(92)31931-1","article-title":"A functional scoring method for the field of binocular single vision","volume":"99","author":"Sullivan","year":"1992","journal-title":"Ophthalmology"},{"key":"2020071615140626800_B27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1365-2265.2001.01347.x","article-title":"TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays","volume":"55","author":"Pedersen","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071615140626800_B28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1089\/thy.2009.0105","article-title":"Assays for thyroid-stimulating hormone receptor antibodies employing different ligands and ligand partners may have similar sensitivity and specificity but are not interchangeable","volume":"20","author":"Pedersen","year":"2010","journal-title":"Thyroid"},{"key":"2020071615140626800_B29","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1530\/EJE-10-1155","article-title":"Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study","volume":"164","author":"Carl\u00e9","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"2020071615140626800_B30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/eje.0.1480491","article-title":"Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience","volume":"148","author":"Prummel","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"2020071615140626800_B31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071615140626800_B32","first-page":"73","article-title":"Ophthalmic Graves' disease: a dual theory of pathogenesis","volume":"4","author":"Nunery","year":"1991","journal-title":"Ophthalmolog Clin North Am"},{"key":"2020071615140626800_B33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000348246","article-title":"Differential involvement of orbital fat and extraocular muscles in Graves' ophthalmopathy","volume":"2","author":"Wiersinga","year":"2013","journal-title":"Eur Thyroid J"},{"key":"2020071615140626800_B34","first-page":"33","article-title":"Pioneers of eye movement research","volume":"1","author":"Wade","year":"2010","journal-title":"Iperception"},{"key":"2020071615140626800_B35","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/j.1460-9568.2011.07695.x","article-title":"Binocular coordination of eye movements\u2014Hering's law of equal innervation or uniocular control?","volume":"33","author":"King","year":"2011","journal-title":"Eur J Neurosci"},{"key":"2020071615140626800_B36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1530\/EJE-13-0973","article-title":"Quality of life improves after strabismus surgery in patients with Graves' orbitopathy","volume":"170","author":"Jellema","year":"2014","journal-title":"Eur J Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/100\/5\/2098\/10855185\/jcem2098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/100\/5\/2098\/10855185\/jcem2098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T02:34:15Z","timestamp":1594953255000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/100\/5\/2098\/2829735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,1]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2014-4557","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,1]]}}}